Abstract Objective To investigate the feasibility and value of diffusion-weighted imaging (DWI) in the prediction and early assessment of response to concurrent chemoradiotherapy (CCRT) for esophageal cancer. Methods A total of 40 patients with pathologically confirmed esophageal cancer who received CCRT were included in the study. Routine 3.0 T MRI and DWI were performed at different time points of treatment. The RECIST standard was adopted to evaluate short-term outcomes and divide the patients into remission group (complete remission and partial remission) and non-remission group (stable disease and progressive disease). Group t-test was used for between-group comparison. The receiver operating characteristic (ROC) curve was used to analyze the change rates of apparent diffusion coefficient (ADC) value at different time points of treatment. Results There were 30 patients in the remission group and 10 patients in the non-remission group. The remission group had a significantly higher increase in ADC value than the non-remission group by the end of the first week of treatment (P=0.000). The maximum diameters of tumors for the emission group and non-remission group at the end of the first week of treatment were not significantly different from those before treatment (66.10 mm vs. 62.63 mm, P=0.407;70.90 mm vs. 68.30 mm, P=0.552). The ADC value before treatment had a negative correlation with the reduction rate of the maximum diameter of tumor (r=－0.680, P=0.000). The area under the ROC curve was the largest at the end of the first week of treatment (Az=0.783). If using 15.5% increase in ADC value by the end of the first week as the threshold value for evaluating tumor response, the sensitivity, specificity, positive predictive value, and negative predictive value were 86.7%, 70.0%, 89.7%, and 63.6%, respectively. Conclusions DWI can be used as a new imaging method for the prediction and early assessment of the response to CCRT for esophageal cancer. The change rate of ADC value by the end of the first week of treatment is sensitive in assessing treatment response, so ADC value can be monitored at this time point.
Chen Wei*,Zhou Shengli,Miao Chongchang et al. Value of DWI for early assessment of response to concurrent chemoradiotherapy for esophageal cancer:a preliminary study[J]. Chinese Journal of Radiation Oncology, 2014, 23(4): 312-316.
Chen Wei*,Zhou Shengli,Miao Chongchang et al. Value of DWI for early assessment of response to concurrent chemoradiotherapy for esophageal cancer:a preliminary study[J]. Chinese Journal of Radiation Oncology, 2014, 23(4): 312-316.
[1] Kumbasar B. Carcinoma of esophagus:radiologic diagnosis and staging[J]. Eur J Radiol,2002,42:170-180. [2] Sendler A. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction[J]. Recent Results Cancer Res,2010,182:167-177. [3] Patterson DM, Padhani AR, Collins DJ. Technology insight:water diffusion MRI—a potential new biomarker of response to cancer therapy[J]. Nat Clin Pract Oncol,2008,5:220-233. [4] Aoyagi T, Shuto K, Okazumi S, et al Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer[J]. Dig Surg,2011,28:252-257. [5] De Cobelli F, Giganti F, Orsenigo E, et al. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment:comparison with tumour regression grade at histology[J]. Eur Radiol,2013,23:2165-2174. [6] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45:228-247. [7] 巴照贵,杨涛,张玉敏,等.表观扩散系数对非小细胞肺癌早期放化疗疗效的评估[J].实用放射学杂志,2012,28:1200-1203,1210. [8] 汪晓红,彭卫军,谭红娜,等.磁共振弥散加权成像监测乳腺癌新辅助化疗疗效的应用价值[J].中华肿瘤杂志,2010,32:377-381. [9] 赵海,高明勇,谭湘萍,等.磁共振扩散加权成像预测、监测直肠癌放化疗效果的价值[J].临床放射学杂志,2011,30:826-829. [10] 韩明,程鑫,张仕状,等.弥散加权成像评价内皮抑素对小鼠结肠癌疗效及其与肿瘤细胞密度的相关性研究[J].实用放射学杂志,2009,25:1191-1194. [11] Laun FB, Fritzsche KH, Kuder TA,et al. Introduction to the basic principles and techniques of diffusion-weighted imaging[J]. Radiologe,2011,51:170-179. [12] Buijs M, Kamel IR, Vossen JA, et al. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging[J]. J Vasc Interv Radiol,2007,18:957-963. [13] 汪晓红,彭红军,谭红娜,等.磁共振弥散加权成像监测乳腺癌新辅助化疗疗效的应用价值[J].中华肿瘤杂志,2010,32:377-381. [14] 高晓,张雪宁,张云亭,等.应用DWI早期评价脑肿瘤伽玛刀治疗效果[J].临床放射学杂志,2011,30:626-630. [15] 梁惠宏,张耀军,陈敏山,等.MR扩散加权成像评价兔Vχ2肝肿瘤射频消融疗效的实验研究[J].实用放射学杂志,2010,26:1670-1674. [16] 张贝,王玮,宦怡,等.DWI评估内分泌治疗前列腺癌疗效及其与PSA的相关性[J].中国医学影像技术,2012,28:554-557. [17] Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy:preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging[J]. Radiology,2010,254:170-178. [18] Pickles MD, Gibbs P, Lowry M, et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer[J]. Magn Reson Imaging,2006,24:843-847. [19] Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy[J]. Neoplasia,2004,6:831-837. [20] Cui Y, Zhang XP, Sun YS,et al. Apparent diffusion coefficient:potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases[J]. Radiology,2008,248:894-900. [21] Aoyagi T, Shuto K, Okazumi S,et al. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer[J]. Dig Surg,2011,28:252-257.
2014, Vol. 23 
